These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 30054313)
1. Lack of central and peripheral nervous system synuclein pathology in R1441G Vilas D; Gelpi E; Aldecoa I; Grau O; Rodriguez-Diehl R; Jaumà S; Martí MJ; Tolosa E J Neurol Neurosurg Psychiatry; 2019 Jul; 90(7):832-833. PubMed ID: 30054313 [No Abstract] [Full Text] [Related]
2. Enteric alpha-synuclein pathology in LRRK2-G2019S Parkinson's disease. Rouaud T; Clairembault T; Coron E; Neunlist M; Anheim M; Derkinderen P Parkinsonism Relat Disord; 2017 Jul; 40():83-84. PubMed ID: 28483388 [No Abstract] [Full Text] [Related]
3. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease. Daher JP Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286 [TBL] [Abstract][Full Text] [Related]
4. Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers. Zhao Y; Perera G; Takahashi-Fujigasaki J; Mash DC; Vonsattel JPG; Uchino A; Hasegawa K; Jeremy Nichols R; Holton JL; Murayama S; Dzamko N; Halliday GM Brain; 2018 Feb; 141(2):486-495. PubMed ID: 29253086 [TBL] [Abstract][Full Text] [Related]
5. LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons. Henderson MX; Peng C; Trojanowski JQ; Lee VMY Acta Neuropathol Commun; 2018 May; 6(1):45. PubMed ID: 29855356 [TBL] [Abstract][Full Text] [Related]
6. Mutations in LRRK2 impair NF-κB pathway in iPSC-derived neurons. López de Maturana R; Lang V; Zubiarrain A; Sousa A; Vázquez N; Gorostidi A; Águila J; López de Munain A; Rodríguez M; Sánchez-Pernaute R J Neuroinflammation; 2016 Nov; 13(1):295. PubMed ID: 27863501 [TBL] [Abstract][Full Text] [Related]
7. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease. Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063 [TBL] [Abstract][Full Text] [Related]
8. Misfolded α-Synuclein Seeding Is Detected in Suspected LRRK2-Parkinson's Disease without Immunohistochemically Detectable α-Synuclein Pathology. Kim A; Martinez-Valbuena I; Keith JL; Kovacs GG; Lang AE Mov Disord; 2024 Jan; 39(1):218-220. PubMed ID: 37986700 [No Abstract] [Full Text] [Related]
9. Reduced content of α-synuclein in peripheral blood leukocytes of patients with LRRK2-associated Parkinson's disease. Pchelina SN; Emelyanov AK; Yakimovskii AF; Miller DW; Shabalina IG; Drozdova AS; Schwarzman AL Bull Exp Biol Med; 2011 Apr; 150(6):679-81. PubMed ID: 22235415 [TBL] [Abstract][Full Text] [Related]
10. Movement disorders rounds: A case of missing pathology in a patient with LRRK2 Parkinson's disease. Agin-Liebes J; Cortes E; Vonsattel JP; Marder K; Alcalay RN Parkinsonism Relat Disord; 2020 May; 74():76-77. PubMed ID: 31734038 [No Abstract] [Full Text] [Related]
11. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Cookson MR Nat Rev Neurosci; 2010 Dec; 11(12):791-7. PubMed ID: 21088684 [TBL] [Abstract][Full Text] [Related]
12. α-synuclein (SNCA) but not dynamin 3 (DNM3) influences age at onset of leucine-rich repeat kinase 2 (LRRK2) Parkinson's disease in Spain. Fernández-Santiago R; Garrido A; Infante J; González-Aramburu I; Sierra M; Fernández M; Valldeoriola F; Muñoz E; Compta Y; Martí MJ; Ríos J; Tolosa E; Ezquerra M; Mov Disord; 2018 Apr; 33(4):637-641. PubMed ID: 29473656 [TBL] [Abstract][Full Text] [Related]
13. Genetic testing for Parkinson's disease in clinical practice. Gasser T J Neural Transm (Vienna); 2023 Jun; 130(6):777-782. PubMed ID: 36929227 [TBL] [Abstract][Full Text] [Related]
14. The emerging role of LRRK2 in tauopathies. Herbst S; Lewis PA; Morris HR Clin Sci (Lond); 2022 Jul; 136(13):1071-1079. PubMed ID: 35815712 [TBL] [Abstract][Full Text] [Related]
16. Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation. Giordana MT; D'Agostino C; Albani G; Mauro A; Di Fonzo A; Antonini A; Bonifati V Mov Disord; 2007 Jan; 22(2):275-8. PubMed ID: 17149743 [TBL] [Abstract][Full Text] [Related]
17. Authors' replies to the comments of Koga et al. on "Movement disorders rounds: A case of missing pathology in a patient with LRRK2 Parkinson's disease". Hickman RA; Vonsattel JP; Agin-Liebes J; Marder K; Alcalay RN Parkinsonism Relat Disord; 2020 Oct; 79():131-132. PubMed ID: 32928644 [No Abstract] [Full Text] [Related]
18. LRRK2 and Parkinson's Disease: From Lack of Structure to Gain of Function. Blanca Ramírez M; Madero-Perez J; Rivero-Rios P; Martinez-Salvador M; Lara Ordonez AJ; Fernandez B; Fdez E; Hilfiker S Curr Protein Pept Sci; 2017; 18(7):677-686. PubMed ID: 26965688 [TBL] [Abstract][Full Text] [Related]
19. Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology. Xiong Y; Neifert S; Karuppagounder SS; Stankowski JN; Lee BD; Grima JC; Chen G; Ko HS; Lee Y; Swing D; Tessarollo L; Dawson TM; Dawson VL eNeuro; 2017; 4(2):. PubMed ID: 28321439 [TBL] [Abstract][Full Text] [Related]
20. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease. Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]